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PEMBANGUNAN KAEDAH MOLEKUL 
BERASASKAN DNA UNTUK PENGESANAN 
GENOTIP SPESIS ENTEROCOCCUS DAN 
RINTANGAN ANTIMIKROBIA 
 
 
ABSTRAK 
 
 
Enterococci muncul sebagai penyebab jangkitan nosokomial yang penting di 
kebanyakan negara di dunia semenjak kurun yang lepas. Strain enterococci yang 
paling biasa dijumpai dalam isolat klinikal ialah E. faecalis dan E. faecium yang 
telah memperoleh kerintangan terhadap gentamicin atau vancomicin. Ujian kultur 
konvensional mengambil 2-5 hari untuk mendapat maklumat lengkap tentang jenis 
organisma dan corak kepekaan antibiotiknya. Oleh sebab itu, kajian ini tertumpu 
terhadap pembangunan suatu ujian reaksi berantai polimerasi berganda untuk 
pengesanan pantas enterococci yang rintang vancomicin dan gentamicin. Ujian ini 
mampu mengesan 8 gen serentak, iaitu 16S rRNA daripada genus Enterococcus, ddl 
daripada E. faecalis dan E. faecium, aacA-aphD yang mengkodkan kerintangan 
tinggi terhadap gentamicin, kerintangan vancomicin yang pelbagai peringkat, iaitu 
vanA, vanB, vanC dan vanD serta satu gen kawalan dalaman. Pasangan pencetus 
khusus dan unik direka supaya julat pengamplifikasi produk berada diantara 150 ke 
1200 bp. Pengkhususan pencetus disah berdasarkan urutan jujukan DNA produk 
reaksi berantai polimerasi berganda and analisa mengecam. Seterusnya, reaksi 
berantai polimerasi berganda ini dijadikan stabil suhu dan ujian kestabilan pantas 
dijalankan pada suhu bilik, 37oC dan 10oC. Kepekaan dan kekhususan ujian ini telah 
dibandingkan deangan kaedah kultur konvensional. Kepekaan analitikal ujian 
diperingkat DNA ialah 1 ng manakala kekhususan analitikal yang dinilai dengan 43 
strain rujukan enterococci dan bukan enterococci adalah 100%. Ujian kestabilan 
 xxi
pantas bagi campuran stabil suhu reaksi berantai polimerasi berganda yang disimpan 
pada 10oC adalah stabil sehingga dua tahun dan enam bulan. Kejituan diagnostik 
yang ditentukan dengan menggunakan sejumlah 543 sampel daripada isolat klinikal, 
ladang ternakan ayam, sampel air dan najis, mendapati 3.9% daripada sampel adalah 
rintang vancomicin dan 16.0% ialah enterococci yang mempunyai kerintangan 
aminoglikosida dwi-fungsi. Kehadiran kawalan dalaman dalam ujian reaksi berantai 
polimerasi berganda membantu dalam penentuan kes negatif palsu. Ujian reaksi 
berantai polimerasi berganda adalah tegap dan boleh memberikan maklumat tentang 
8 gen penting untuk pengesanan spesis Enterococcus yang paling biasa dan corak 
kerintangan antibiotiknya. Ujian reaksi berantai polimerasi yang dibangunkan dalam 
kajian ini boleh digunakan sebagai alat pemantauan yang berkesan untuk kajian 
prevalens enterococci dan corak rintangan antibiotiknya dalam hospital dan haiwan 
ternakan.    
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DEVELOPMENT OF A DNA-BASED MOLECULAR 
METHOD FOR THE RAPID DETECTION OF 
ENTEROCOCCUS SPECIES AND ANTIMICROBIAL 
RESISTANCE GENOTYPES 
 
ABSTRACT 
 
 
 Enterococci have emerged as a significant cause of nosocomial infections in 
many parts of the world over the last decade. The most common enterococci strains 
present in clinical isolates are E. faecalis and E. faecium, which have acquired 
resistance to either gentamicin or vancomycin. The conventional culture test takes 2-5 
days to yield complete information of the organism and its antibiotic sensitivity 
pattern. Hence, our present study was focused on developing a multiplex PCR assay 
for the rapid detection of vancomycin and bifunctional aminoglycoside resistant 
enterococci. This assay simultaneously detects 8 genes namely 16S rRNA of 
Enterococcus genus, ddl of E. faecalis and E. faecium, aacA-aphD that encodes high 
level gentamicin resistance (HLGR), multilevel vancomycin resistant genotypes such 
as vanA, vanB, vanC and vanD and one internal control gene. Unique and specific 
primer pairs were designed to amplify the 8 genes with the PCR products ranging from 
150 to 1200 bp. The specificity of the primers were confirmed by DNA sequencing of 
the multiplex PCR products and BLAST analysis. The sensitivity and specificity of 
multiplex PCR assay was evaluated against the conventional culture method. The 
multiplex PCR was thermostabilized and an accelerated stability test was evaluated at 
room temperature, 37oC and 10oC. The analytical sensitivity of the assay was found to 
be 1 ng at the DNA level while the analytical specificity was evaluated with 43 
reference enterococci and non-enterococcal strains and was found to be 100%. The 
thermostabilized multiplex PCR mix stored at 10oC was stable up to two and a half 
 xxiii
years by the accelerated stability test. The diagnostic accuracy was determined using a 
total of 543 samples from clinical isolates, poultry farms, water samples and stool 
samples, which showed that 3.9% of the samples were vancomycin resistant and 
16.0% were bifunctional aminoglycoside resistant enterococci. The presence of an 
internal control in the multiplex PCR assay helped to rule out false negative cases. The 
multiplex PCR assay is robust and can give information about the 8 genes that are 
essential for the identification of the most common Enterococcus species and their 
antibiotic susceptibility pattern. The PCR assay developed in this study can be used as 
an effective surveillance tool to study the prevalence of enterococci and their antibiotic 
resistance pattern in hospitals and farm animals. 
 
 1
CHAPTER ONE: INTRODUCTION 
 
 
1.1  INTRODUCTION 
1.1.1 History and significance of Enterococcus  
Enterococci are Gram-positive cocci that occur singly, in pairs, or as short chains 
(Facklam et al., 2002). Their complex interaction with humans in food manufacturing, 
ever-present in humans and animals alimentary tract, in soil, water and food causes 
serious human and animal infections. These diverge characteristics make it an important 
group of bacteria in human life. Enterococcus is closely related to the streptococci 
(Facklam et al., 2002). In the 1930s, the Lancefield serological typing system was 
established, which classified enterococci as group D streptococci and were differentiated 
from non-enterococcal group streptococci (Streptococcus bovis) (Lancefield, 1933, 
Cetinkaya et al., 2000). The enterococcal group was introduced and used by Sherman in 
1938, to describe streptococci that grew at 10 to 45oC, in broth with pH 9.6 and in broth 
containing 6.5% NaCl, and survived at heating to 60oC for 30 min (Sherman, 1938, 
Cetinkaya et al., 2000). In 1970, the enterococcal streptococci genus was proposed by 
Kalina based on cellular arrangement and phenotypic characteristics, whereby S. faecalis 
and S. faecium of these two taxons be named Enterococcus (Kalina, 1970, Facklam et al., 
2002). However, the proposal was not accepted and the use of Streptococcus genus 
continued. Finally in 1984, Schleifer and Kilpper-Balz provided sufficient genetic 
evidence of the difference of S. faecalis and S. faecium from the other members of 
Streptococcus genus to merit a separate genus (Schleifer and Kilpper-Balz, 1984, 
Cetinkaya et al., 2000, Facklam et al., 2002). The streptococcal species S. faecalis and S. 
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faecium were excluded from Streptococcus to form the Enterococcus genus (Schleifer 
and Kilpper-Balz, 1984).  
Presently, based on standard laboratory procedures for species identification using 
phenotypic tests and molecular-based methods such as DNA-DNA reassociation (Niemi 
et al., 1993), 16S rRNA gene sequencing (Devriese et al., 1995, Vandamme et al., 1996) 
and whole-cell protein analysis (Teixeira et al., 1995); a total of 27 Enterococcus species 
have been included in the Enterococcus genus (Table 1.1) (Facklam et al., 2002). The 
phylogenetic analysis of catalase-negative, Gram-positive cocci based on the comparison 
of 1,400 bases of the 16S rRNA gene has revealed that the Enterococcus is more closely 
related to Vagococcus, Tetragenococcus and Carnobacterium than to the phenotypically-
associated Streptococcus and Lactococcus genera (Collins et al., 1989, Aguirre and 
Collins, 1992, Devriese et al., 1993, Facklam et al., 2002).  
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Table 1.1. Taxonomic studies of the genus Enterococcus. 
 
No. Species Year identified (method) 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
 
 
E. faecalis 
E. faecium 
E. avium 
E. casseliflavus 
E. durans 
E. gallinarums 
E. malodoratus 
E. hirae 
E. mundtii 
E. raffinosus 
E. pseudoavium 
E. cecorum 
E. columbae 
E. saccharolyticus 
E. dispar 
E. sulfureus 
E. asini 
E. villorum 
E. haemoperoxidus 
E. moraviensis 
E. ratti 
E. porcinus 
E. pallens 
E. gilvus 
E. seriolicida 
E. solitarius 
E. flavescens 
 
1983 (DNA analysis); 1993 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1983 (DNA analysis); 1994 (protein analysis) 
1985 (DNA analysis); 1994 (protein analysis) 
1986 (DNA analysis); 1993 (protein analysis) 
1989 (DNA analysis); 1994 (protein analysis) 
1989 (DNA analysis); 1994 (protein analysis) 
1989 (DNA analysis); 1994 (protein analysis) 
1990 (DNA analysis); 1994 (protein analysis) 
1984 (DNA analysis); 1994 (protein analysis) 
1991 (DNA analysis); 1994 (protein analysis) 
1986 (DNA analysis); 1994 (protein analysis) 
1998 (DNA analysis); 2001 (protein analysis) 
2001 (DNA analysis); 2001 (protein analysis) 
2001 (DNA analysis) 
2001 (DNA analysis) 
1998 (DNA analysis); 2001 (protein analysis) 
2001 (DNA analysis); 2001 (protein analysis) 
(DNA analysis); (protein analysis) 
(DNA analysis); (protein analysis) 
1991 (DNA analysis); 1991 (protein analysis) 
1998 (DNA analysis); (protein analysis) 
1992 (DNA analysis); 1997 (protein analysis) 
 
 
Note: Adapted and slightly modified from reference (Facklam et al., 2002) (Appeared as 
table 2 and page 6-7 in the source of original). 
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1.1.2 Epidemiology of Enterococcus 
In the past decades, enterococci have emerged as important nosocomial pathogens 
in many countries around the world (Moellering, 1992). Most enterococci exhibit a high 
extent of antimicrobial resistance, particularly to vancomycin. Vancomycin resistant 
enterococci (VRE) strains also show resistance to penicillins and high-level resistance to 
aminoglycosides (Malani et al., 2002). E. faecium is more resistant than E. faecalis that 
accounted for 5-15% of enterococcal infections (Cetinkaya et al., 2000).  
The E. faecalis species was reported to be responsible for most infections in the 
community, long-term care unit and hospitals (Graninger and Ragette, 1992, Patterson et 
al., 1995, Malani et al., 2002). E. faecalis is more likely to be susceptible to vancomycin, 
but resistant to high-level gentamicin and other aminoglycosides that make patients with 
serious infections like endocarditis difficult to treat. 
Currently, enterococci that accounted for around 20% of nosocomial infections 
isolated from intensive care units (ICU) patients and approximately 15% from non-ICU 
patients are VRE (Fridkin and Gaynes, 1999, Malani et al., 2002). Fortunately, in 
Malaysia, only 3 cases of VRE isolated from clinical specimens from year 1996 to 2006 
have been reported (Riley et al., 1996, Raja et al., 2005, Zubaidah et al., 2006).  
It is very important to identify the reservoirs for colonization and the routes of 
transmission of enterococci since there are limited therapeutic options for treatment of 
VRE infections (Malani et al., 2002). The role of widespread and indiscriminate use of 
antimicrobials is obviously encouraging the colonization of VRE.  
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1.1.3 Classification 
Current classification and identification of enterococci are done by conventional 
or molecular tests.  
1.1.3.1 Conventional methods for identification of enterococcal species 
The enterococcal species are separated into five groups based on conventional 
(biochemical) phenotypic tests such as acid formation in mannitol and sorbose broths and 
hydrolysis of arginine (Tables 1.2 and 1.2.1). However, this method may require long 
incubation time (2 -10 days) (Facklam et al., 2002).  
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                               Table 1.2. Phenotypic characteristics used for identification of Enterococcus species. 
 
 
Species 
Phenotypic characteristica. 
M
AN
SOR ARG ARA SBL RAF TEL MOT PIG SUC PYU MGP
Group I 
E. avium 
E. malodoratus 
E. raffinosus 
E. pseudoavium 
E. saccharolyticus 
E. pallens 
E. gilvus 
 
Group II 
E. faecalis 
E. faecium 
E. casseliflavus 
E. mundtii 
E. gallinarum 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
- 
- 
- 
- 
- 
 
 
 
 
- 
- 
- 
- 
- 
- 
- 
 
 
+ 
+ 
+ 
+ 
+ 
 
 
 
+ 
- 
+ 
- 
- 
- 
- 
 
 
- 
- 
+ 
+ 
+ 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
+ 
- 
v 
v 
- 
 
 
 
 
- 
+ 
+ 
- 
+ 
+ 
+ 
 
 
- 
v 
+ 
+ 
+ 
 
 
 
 
- 
- 
- 
- 
- 
- 
- 
 
 
+ 
- 
  -* 
- 
- 
 
 
 
 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
  -* 
- 
  -* 
 
 
 
 
- 
- 
- 
- 
- 
+ 
+ 
 
 
- 
- 
+ 
+ 
- 
 
 
 
 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
 
 
  +* 
+ 
  +* 
+ 
+ 
 
 
 
 
+ 
+ 
+ 
+ 
- 
- 
+ 
 
 
+ 
- 
v 
- 
- 
 
 
 
 
v 
v 
v 
+ 
+ 
+ 
- 
 
 
- 
- 
+ 
- 
+ 
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                     Table 1.2. Continued. 
   
 
Species 
Phenotypic characteristica. 
MAN SOR ARG ARA SBL RAF TEL MOT PIG SUC PYU MGP
Group III 
All 7 species refer 
to table 1.2.1) 
 
Group IV 
E. asini 
E. sulfureus 
E. cecorum 
 
Group V 
E. casseliflavus 
E. gallinarum 
E. columbae 
 
 
- 
 
 
 
- 
- 
- 
 
 
+ 
+ 
+ 
 
- 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
+ 
 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
v 
 
 
 
- 
- 
- 
 
 
+ 
+ 
+ 
 
- 
 
 
 
- 
- 
+ 
 
 
v 
- 
+ 
 
v 
 
 
 
- 
+ 
+ 
 
 
+ 
+ 
+ 
 
v 
 
 
 
- 
- 
- 
 
 
v 
- 
- 
 
- 
 
 
 
- 
- 
- 
 
 
+ 
+ 
- 
 
- 
 
 
 
- 
+ 
- 
 
 
+ 
- 
- 
 
v 
 
 
 
+ 
+ 
+ 
 
 
+ 
+ 
+ 
 
v 
 
 
 
- 
- 
+ 
 
 
v 
- 
+ 
 
v 
 
 
 
- 
+ 
- 
 
 
+ 
+ 
- 
 
 
         Note: Adapted from reference (Facklam et al., 2002) (Appeared as table 3 and page 10 in the source of original). 
 
 
 a. MAN, mannitol; SOR, sorbose; ARG, arginine; ARA, arabinose; SBL, sorbitol; RAF, raffinose; TEL,  0.04% tellurite; MOT, 
motility; PIG, pigment; SUC, sucrose; PYU, pyruvate; MGP, methyl-α-D-glucopyranoside; +, >90% positive; -, <10% positive; V, 
variable; +* or -*, occasional exceptions (<3% of strains show aberrant reactions).  
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  Table 1.2.1. Phenotypic characteristics used for identification of Enterococcus species Group III. 
 
 
Species 
Phenotypic characteristica. 
LM PYU HIP TEL ARA GYL RAF SUC TRE XYL MGP 
 
E.durans 
E. porcinusb. 
E. ratti 
E. hirae 
E. dispar 
E. faecalisc. 
E. faeciumc. 
 
 
A/C 
A/- 
-/- 
A/- 
A/- 
A/C 
A/v 
 
-/0 
-/0 
-/0 
-/6 
+/100 
+/76 
-/0 
 
+/82 
-/0 
v/60 
-/3 
+/100 
-/13 
v/56 
 
-/0 
-/0 
-/0 
-/0 
-/0 
+/88 
-/6 
 
-/0 
-/0 
-/0 
-/0 
-/0 
-/0 
+/100 
 
-/0 
-/0 
-/0 
-/5 
+/100 
-/12 
-/6 
 
-/0 
-/0 
-/0 
+/100 
+/100 
-/0 
-/13 
 
-/0 
-/0 
-/0 
+/100 
+/100 
-/12 
v/38 
 
+/100 
+/100 
-/20 
+/100 
+/100 
-/20 
+/75 
 
-/ 
+/100 
-/ 
-/ 
-/ 
-/ 
-/ 
 
-/0 
-/0 
-/0 
-/0 
+/100 
-/0 
-/0 
         
Note: Adapted from reference (Facklam et al., 2002) (Appeared as table 4 and page 11 in the source of original). 
 
 
a. LM, litmus milk, A, acid, C, clot formation; PYU, pyruvate utilization; HIP, hippurate hydrolysis; TEL, tolerance to 0.04% tellurite; 
ARA, GYL, RAF, SUC, TRE, XYL, MGP, acid formation in broth containing 1% arabinose, glycerol, raffinose, sucrose, trehalose, 
xylose, methyl-α-D-glucopyranoside, respectively; + or – or v/ number, interpreration/ percent positive; +, 85% or more of the strains 
positive, -, 15% or less than the strains positive; v, variable reactions (16 to 84% positive); b. E. villorum has similar phenotypic 
characteristics but has not been tested in conventional tests;  c. Mannitol-negative variants. 
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1.1.3.2 Molecular tests for identification of Enterococcus species 
During the last decade, attempts to develop more rapid and accurate 
identification methods by application of molecular techniques have expanded 
dramatically. Molecular-based tests such as DNA-DNA hybridization, 16S rRNA genes 
sequencing and gas-liquid chromatography of fatty acids to analyze different 
Enterococcus cells molecules for taxonomic purposes have the potential to be adaptable 
for use in microbiology laboratories (Facklam et al., 2002).  
Other molecular methods that have been applied for the identification of 
Enterococcus species are WCP profile analysis, vibrational spectroscopic analysis, 
RAPD analysis, sequencing analysis of the 16S rRNA gene, fragment length 
polymorphism analysis of amplified 16S rRNA, sequencing of the domain V of 23S 
rRNA gene, amplification of the rRNA intergenic spacer, sequencing of ddl genes, 
amplification of ddl and van genes, sequencing of the sodA gene, sequencing and 
probing of the cpm60 gene, amplification and probing of the efaA  gene, amplification 
and probing of the ace gene, amplification and sequencing of the tuf gene and lastly, 
amplification of the pEM1224 gene. 
 
 10
1.1.4  Properties of Enterococcus 
1.1.4.1 Physical characteristics 
1.1.4.1.1 Phenotypic typing methods 
Phenotypic characterization methods that were previously used in 
epidemiological investigation have included biotyping and antibiotyping, based on 
physiological (Kuhn et al., 1995), antimicrobial resistance characteristics (Luginbuhl et 
al., 1987, Murray, 1992) and serotyping (Sharpe and Shattock, 1952, Sharpe, 1964, 
Smyth et al., 1987 Maekawa et al., 1992). Although these approaches yielded useful 
information, they are complicated, highly irreproducible, gave insufficient 
discrimination, time-consuming and difficult to interpret. These drawbacks have limited 
their value in epidemiological studies (Facklam et al., 2002).  
1.1.4.1.2 Molecular typing methods 
Among the earliest molecular techniques developed and used were the analysis 
of plasmid profiles and restriction enzyme analysis of genomic DNA by electrophoresis 
(Hall et al., 1992, Lacoux et al., 1992, Bodnar et al., 1996, Savor et al., 1998, Quednau 
et al., 1999, Facklam et al., 2002). Yet, the inconsistencies in plasmid yield and 
difficulties in accurate interpretation of electrophoretic profiles that failed to 
discriminate among enterococcal strains were noted (Facklam et al., 2002).   
Currently, the gold standard for the epidemiological analysis of nosocomial enterococcal 
infections is the PFGE profiles of SmaI-digested genomic DNA. This is the single most 
useful and reliable typing method for enterococci. However, the use of specialized 
equipments, lack of standardized procedures and difficult interpretation of PFGE 
banding profiles limit the extensive application of this technique (Facklam et al., 2002).    
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1.1.4.2 Growth and culture characteristics  
Enterococci are facultative anaerobes that grow optimally at 35oC. The growth of 
enterococci can be supported by brain-heart infusion with 5% sheep blood and any blood 
agar base containing 5% animal blood. Some strains of E. faecalis are beta-hemolytic on 
agar bases containing rabbit, horse, or human blood but not on agar containing sheep 
blood. However, some E. durans strains are beta-hemolytic regardless of the type of 
blood used. The other species are alpha or gamma-hemolytic (Facklam et al., 2002). If 
the sample to be cultured may contain Gram-negative bacteria, bile-esculin azide 
(Enterococcosel agar) (Sabbaj et al., 1971), Pfizer selective Enterococcus, Enterococci 
broth (Merck, Darmstadt, Germany) and other commercially prepared medium 
containing azide are primary isolation media (Facklam et al., 2002). The azide inhibits 
Gram-negative bacteria, and enterococci appear as black colonies of esculin hydrolysis. 
Besides that, Columbia colistin-nalidixic acid agar (CNA) (Ellner et al., 1966) and 
phenylethyl alcohol agar (PEA) (Dayton et al., 1974) have been used successfully to 
isolate enterococci (Facklam et al., 2002).  
The rise in the increase of vancomycin resistance among enterococci makes it 
important and necessary to isolate VRE for the control of the spread of these organisms 
in hospital environments (Ieven et al., 1999, Cetinkaya et al., 2000, Facklam et al., 
2002). A variety of different selective-enrichment media have been used for the isolation 
of VRE from fecal specimens (stool samples and rectal swabs) like Mueller-Hinton agar 
(MHA) (Willey et al., 1992), brain-heart infusion agar (BHI) (Swenson et al., 1994), 
Enterococcosel agar (Ieven et al., 1999, Roger et al., 1999) and Enterococci broth 
supplemented with 6 µg/ml of vancomycin. 
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1.2   CLINICAL MANIFESTATIONS, PATHOGENESIS, TREATMENT AND               
        PREVENTION OF ENTEROCOCCUS 
1.2.1 Reservoirs and mode of transmission 
Enterococci are normal flora in the gastrointestinal tract of humans and many 
other animals. E. faecalis is most common and abundant of enterococci followed by E. 
faecium. Even though enterococci are found throughout the whole gastrointestinal tract, 
both E. faecalis and E. faecium are found in the highest number in the colon and also a 
low number in the oral cavity (Chenoweth, 1990). In addition, E. faecalis is a 
predominant normal inhabitant in the genital tract (Malani et al., 2002).  
The emergence of VRE has made it important to understand its colonization 
pattern, because once it colonizes the host, it may persist for months or years (Lai et al., 
1997, Roghmann et al., 1997b, Bonten et al., 1998, Malani et al., 2002).  
In the 1980s, the rise in nosocomial acquisition and the subsequent spread of 
aminoglycoside resistant enterococci and VRE in the 1990s have demonstrated the 
transmission of enterococci among patients in the hospital ward (Handwerger et al., 
1993, Boyce et al., 1994, Saurina et al., 1997, Malani et al., 2002). The spread of VRE 
into the environment is likely to occur in the diarrhea patients ward (Boyce et al., 1994, 
Cetinkaya et al., 2000). The carriage of enterococci by the hands of health care workers 
is the presumed mode of transmission from patient to patient and by way of 
contaminated medical equipments (Cetinkaya et al., 2000, Hayden, 2000, Mayhall, 
1999, Malani et al., 2002). Contaminated environmental surfaces and medical 
equipments in the hospital ward may serve as a reservoir for the bacteria in the hospital 
(Cetinkaya et al., 2000). Another suggested mode of transmission of enterococci is by 
direct inoculation onto intravenous or urinary catheters, but this is more likely to result 
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in gastrointestinal tract colonization with the acquired strain, which subsequently 
become the patient’s normal flora (Zervos et al., 1987a, Malani et al., 2002). The use of 
broad-spectrum antimicrobials in hospitals causes the normal flora to acquire antibiotic 
resistance and persist in the gastrointestinal tract. Subsequently, the infections that arise 
could be due to this acquired strain (Malani et al., 2002). The spread of VRE within a 
hospital unit (Karanfil et al., 1992, Handwerger et al., 1993, D'Agata et al., 2001), 
between hospitals (Moreno et al., 1995, Donskey et al., 1999b) and even from state to 
state (Chow et al., 1993) has been documented. This may be caused by the increased 
movement of colonized patients among different health care centers. Although it is 
uncommon, non-hospitalized individuals may acquire VRE through contaminated 
animal-based food products that serve as a reservoir (Moreno et al., 1995, Trick et al., 
1999, Cetinkaya et al., 2000, Malani et al., 2002). 
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1.2.2 Pathogenesis and immune responses  
Enterococcal is a commensal organism in the gastrointestinal tracts of various 
organisms, from humans to insects. However, 100 years ago enterococci were 
recognized as capable of causing serious infections and in the past two decades, it has 
become resistant to many groups of antimicrobial including the antimicrobial of last 
resort, vancomycin. In this era of modern medicine, the balance in commensalism is 
disrupted, whereby organisms acquiring new traits can result in the breakdown of the 
host’s ability to hold commensal organisms in check, and this enables the organism to 
colonize new niches of the host that the host is incapable of adequately defending 
(Gilmore et al., 2002). 
Enterococci occur as a commensal in the human colon (~ 108 CFU/g of feces) 
(Noble, 1978, Huycke et al., 1998) and also can be isolated from the environment (fecal 
material contamination). The emerging literature evidence suggests that enterococci may 
be highly host adapted (enterococci colonizing specific hosts), many clinical isolates are 
virulent species that are distinct from those that colonize the GI tracts of healthy 
individuals. The factors that cause enterococci-adapted host specificity include species-
specific mucin characteristics, co-resident GI tract flora composition, diet and motility 
rates (Kararli, 1995). Based on Escherichia coli that have both commensal and 
pathogenic roles, an emerging concept that human commensal enterococcal strains are 
genetically distinct from pathogenic isolates was built (Gilmore et al., 2002). 
The virulent enterococcal lineages are able to cause hospital ward outbreaks 
involving multiple patients as a clonal outbreak (Huycke et al., 1991, Murray et al., 
1991, Thorisdottir et al., 1994, Chow et al., 1993, Suppola et al., 1999, Van Den Braak 
et al., 1999), while commensal strains do not. The acquisition of additional traits on 
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mobile genetic elements enhanced its ability to destabilize the commensal relationship 
and cause disease (Hacker and Kaper, 2000). Enterococci traits that caused clonal 
outbreaks are antimicrobial resistances (Murray et al., 1991, Thorisdottir et al., 1994, 
Chow et al., 1993, Suppola et al., 1999, Van Den Braak et al., 1999) and expression of 
enterococcal cytolysin (Huycke et al., 1991, Gilmore et al., 2002).  
The effect of antimicrobial introduction and its widespread usage on 
enterococcal infection is unknown, but literature reviews showed that enterococcal 
infection could have occurred prior to the introduction and widespread use of 
antimicrobials (Gilmore et al., 2002).  
Enterococci possess an intermediate level of virulence compared to streptococci 
and lactococci, thus Enterococcus was term as “facultative parasite” (Andrewes, 1906). 
Since the pre-antibiotic era, E. faecalis and E. faecium are the major cause of 
enterococcal infections (Huycke et al., 1998). Translocation of enterococci from intra-
abdomial abscesses, intravenous catheters, genitourinary tract and most GI tract are 
causes of enterococcal bacteremia (Cheung et al., 1997, Shlaes et al., 1981, Mundy et 
al., 2000, Gilmore et al., 2002).  
Nosocomial isolates analysis reveals that different patient isolates are clonally 
related (Zervos et al., 1987a). Colonization of GI tract upon hospitalization by virulent 
lineages eliminates many endogenous flora and caused overgrowth of pathogenic 
enterococcal strains. The indigenous enterococci and nosocomial enterococci do not 
compete for the same location and this perhaps explain why nosocomial strains with 
particular traits are able to colonize certain GI tract location that indigenous enterococci 
cannot. GI tract serves as area for multiplication of numbers of nosocomial enterococci, 
and when opportunities arise, the organism will spread from the primary colonization 
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site to urinary tract, postsurgical wound site or bloodstream, where nosocomial strain 
with its additional traits enable it to colonize, evade host clearance mechanisms and 
induce pathology (Gilmore et al., 2002).  
 
Among bacterial virulence factors that influence the host-parasite relationship are:  
(A)  Secreted factors:  
(i)  Cytolysin encoded in a complex operon (cyl) consisting of 8 genes and it is a 
bacterial toxin expressed by some strains of E. faecalis that displays both hemolytic and 
bactericidal activity in the pathogenesis of enterococcal infection. Enterococcal 
infections have two critical components; inflammation, which is treatable with 
corticosteroid, and toxin-mediated organ destruction, which is untreatable by either 
corticosteroid or antimicrobial. Cytolysin caused pathogenicity of E. faecalis by direct 
tissue damage. The hemolytic toxin enables E. faecalis to manufacture cytochromes 
from exogenous hemin by hemolysin erythrocytes that allow for aerobic respiration and 
greater growth yield to explain the enhanced presence of cytolytic strains in the 
bloodstream (Ritchey and Seeley, 1974, Pritchard and Wimpenny, 1978, Janda and 
Abbott, 1993);  
(ii)   Bacterial proteases function to provide peptide nutrients to organisms and work as 
virulence factors, which cause direct and indirect host tissue damage, indirect 
degradation of host connective tissues by activating host matrix metalloproteases (Burns 
et al., 1996, Okamoto et al., 1997); deregulating critical host processes to facilitate 
microbial invasion and survival in host environments (Maeda and Yamamoto, 1996); 
deregulating key components of the host immune system by degrading either 
immnunoglobulins or complement pathways (Schultz and Miller, 1974, Plaut, 1983, 
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Sundqvist et al., 1985, Prokesova et al., 1992); degrading specific host proteins resulting 
in production of toxins (Tonello et al., 1996, Duesbery et al., 1998); activating viruses 
either directly or indirectly (Tashiro et al., 1987); processing other bacterial virulence 
factors (Booth et al., 1984, McGavin et al., 1997); and mediating direct degradation of 
host connective tissues or tissue proteins (Lantz et al., 1991, Travis et al., 1994, Gilmore 
et al., 2002). E. faecalis secrete two proteases, namely, gelatinase or coccolysin, (gelE, a 
metalloprotease) to inactivate human endothelin (a vasoactive peptide). Hospital isolates 
show high frequency compared with fecal isolates from healthy volunteers and studies 
found that E. faecium strains are not gelatinase-producer (Coque et al., 1995, Elsner et 
al., 2000).  Serine proteases (sprE gene) are also secreted that down-regulate the 
expression of surface proteins, such as protein A, coagulase and fibronectin-binding 
protein (Recsei et al., 1986, Novick et al., 1993, Lebeau et al., 1994, Cheung et al., 
1997, Ji et al., 1997, Gilmore et al., 2002).  
 
(B)  Enterococcal adhesions: 
(i)  Aggregation substances are surface-localized protein encoded by pheromone-
responsive, self-transmissible plasmids that mediate binding or interaction between 
donor and recipients bacterial cells (Clewell, 1993), mediating enterococcal binding to 
eukaryotic cells and as a binding factor to resistance to immune clearance by interfering 
with PMN-mediated killing that caused E. faecalis to survive within polymorphonuclear 
neutrophils (PMNs) following phagocytosis (Rakita et al., 1999). In summary, 
aggregation substances have multiple roles for enterococcal virulence: it disseminates 
plasmid-encoded virulence factors, such as enterococcal cytolysin and antimicrobial 
resistance determinants, promoting adherence of E. faecalis to epithelial cell surface, 
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promote internalization and survival within intestinal macrophages and PMNs. The 
cytolysin and aggregation substances act synergistically to enhance virulence by 
facilitating quorum achievement and activate cytolysin, resulting in tissue damage and 
deeper tissue invasion.  
(ii)  Enterococcal surface protein (esp) expressed by enterococci as a large-molecular-
weight cell-surface-localized protein; that mediates biofilm formation (Toledo-Arana et 
al., 2001) – esp has been linked to epidemic vancomycin-resistant strains of E. faecium 
(Willems et al., 2001) and were found to be responsible for hospital outbreaks in the 
United States, Europe and Australia. Esp functions as an adhesive that mediates binding 
to bladder uroepithelial cells (Shankar et al., 2001). The esp gene is located closely to 
cytolysin operon on the chromosome of the enterococci. The clustering of these and 
other virulence related genes, such as regions encoding several transposases and 
recombinases are characteristics of pathogenicity islands and were observed to be highly 
dynamic (Hacker and Kaper, 2000). 
(iii)  Ace, an adhesion of E. faecalis to host cells collagen (Patti et al., 1994, Casolini et 
al., 1998, Joh et al., 1999) fiber that are produced during infection, but the role in 
causing infection is still unknown.  
(iv)  E. faecalis antigenA (EfaA) shown to have adhesion, virulence and ATP-binding 
cassette transporter systems (Jenkinson, 1994), but its role in pathogenesis of 
enterococcal infection is still unknown (Gilmore et al., 2002). 
 
(C)  Enterococcal capsule and cell wall: 
Cell wall components (carbohydrates and teichoic acids), composition and structure that 
drive the complex interactions between bacteria and the host immune system (Knirel, 
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1990, Nilsson et al., 1997, Thakker et al., 1998, Portoles et al., 2001, Tzianabos et al., 
2001) and the capsules that protect the organism from phagocytosis and vary under 
immune selection (Roche and Moxon, 1995, Claverys et al., 2000); 
(i)  variable capsular carbohydrate may be compositionally and immunologically 
distinct. The virulence of cps pathway showed ability to persist within lymphatic tissue; 
(ii)  common cell wall polysaccharide - enterococcal polysaccharide antigen (epa) are  
reported to be involved in biosythesis of an enterococcal polysaccharide antigen during 
infection in humans (Gilmore et al., 2002). 
 
(D)  Toxin metabolic products of enterococci: 
Enterococci are rarely able to produce quantities of extracellular superoxide that rival 
activated neutrophil (Huycke et al., 1996). Thus, isolates from human bloodstream have 
more of this metabolic activity capacity and are more common in the species faecalis 
than faecium. The production of superoxide results in the human colonic epithelial cells 
chromosomes fragmentation and may relate to colon carcinoma etiology or overt tissue 
damage, which may facilitate bloodstream access by enterococci (Gilmore et al., 2002). 
 
Although E. faecium increasingly causes infections in human, the genetic determinants 
coding for its virulence factors remain poorly characterized. Only the esp gene is 
common among E. faecium strains infection (Willems et al., 2001). Other traits that 
work as virulence factors in E. faecalis (hemolysin, aggregation substance and gelatinase 
or serine protease) are rare in E. faecium (Gilmore et al., 2002). 
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1.2.3 Clinical disease and complications 
Enterococci cause a variety of clinical infections. In some infections, other 
microorganisms are frequently implicated, making it difficult to assess whether the 
disease manifestations are a result of infection of the tissue by enterococci or whether 
these comparatively avirulent organisms are simply playing a minor role in the infection 
(Gilmore et al., 2002). However, in endocarditis, enterococci are clearly the cause of this 
life-threatening disease and accounted for 10 to15% of endocarditis cases (Gilmore et 
al., 2002). The resistance of enterococci to vancomycin and high level aminoglycosides 
make treatment of endocarditis difficult (Cetinkaya et al., 2000, Gilmore et al., 2002). 
An effective treatment requires the synergistic effect of these two drugs (Gilmore et al., 
2002). Thus, in VRE or high-level aminoglycoside resistant enterococcal endocarditis, 
antimicrobial treatment often failed, and the surgery to remove the infected valve is 
critical (Gilmore et al., 2002). E. faecalis is the most common cause of endocarditis, 
especially in older men. Valvular infections are usually caused by bacteremia arising 
from the genitourinary or gastrointestinal tract. The increase in left sided involvement is 
much more common. The increase in prosthetic valve enterococcal endocarditis cases 
are caused by the increasing use of valvular prostheses on older men (high risk 
enterococcal bacteremia) and the mortality rate is at 15 to 20% (Rice et al., 1991, 
Megran, 1992, Gilmore et al., 2002). In the older age, presence of multiple underlying 
illnesses and multidrug-resistant enterococci cause the most problem in management of 
endocarditis (Landman and Quale, 1997, Gilmore et al., 2002).  
Besides that, enterococci are the third leading cause of nosocomial bacteremia 
(Cetinkaya et al., 2000) and VRE cause 25% of enterococcal bacteremia in ICU 
(Gilmore et al., 2002). The overall mortality rate resulting from enterococcal bacteremia 
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is 30 to 75% and some studies have shown that E. faecium bacteremia has a higher 
mortality rate than E. faecalis (Maki and Agger, 1988, Noskin et al., 1995a, Gilmore et 
al., 2002). The urinary tract is the most common source of bacteremia. In addition, intra-
abdominal or biliary tract, infected intravenous catheter or a soft tissue infection can also 
lead to polymicrobial infection (Maki and Agger, 1988, Patterson et al., 1995, Gilmore 
et al., 2002). Enterococci seed at single organs and never cause metastatic abscesses 
after a bacteremia episode (Gilmore et al., 2002). Older people who have multiple 
underlying diseases, like cancer, heart disease, diabetes mellitus and prior surgery are at 
risk of developing enterococcal bacteremia (Maki and Agger, 1988, Terpenning et al., 
1988, Patterson et al., 1995, Gilmore et al., 2002).  
Urinary tract infection is the most common infection by enterococci (Gilmore et 
al., 2002). Enterococcal lower urinary tract infections (cystitis, prostatitis, and 
epididymitis) and upper urinary tract infections that can lead to bacteremia are common 
in older men (Gilmore et al., 2002). In ICU, enterococci cause almost 15% of 
nosocomial urinary tract infections (Fridkin and Gaynes, 1999, Gilmore et al., 2002,). 
The enterococcal urinary tract infections acquired from hospitals or long-term care 
settings are more likely to be resistant to many antimicrobials, especially vancomycin 
(Terpenning et al., 1994, Gilmore et al., 2002). The second most common source for 
enterococcal bacteremia is intra-abdominal or pelvic wounds or abscesses (Maki and 
Agger, 1988, Graninger and Ragette, 1992, Noskin et al., 1995a, Patterson et al., 1995) 
and it is isolated from 15% of surgical site infection wounds among ICU patients 
(Fridkin and Gaynes, 1999, Gilmore et al., 2002). Enterococci are frequently isolated as 
a module of mixed microbial flora from intra-abdominal, pelvic and soft-tissue 
infections specimens, and rarely cause monomicrobial infection at these sites (Gilmore 
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et al., 2002). The importance of enterococci in wounds and abscesses is yet unclear. 
However, in cases of peritonitis occuring secondary to cirrhosis or to chronic peritoneal 
dialysis, enterococci can cause monomicrobial infection. Meningitis, hematogenous 
osteomyelitis, septic arthritis and pneumonia caused by enterococci, are less common 
but these are caused by broad-spectrum antibiotic use in debilitated or 
immunocompromised patients (Gilmore et al., 2002).   
 
1.2.4 Antimicrobial resistance 
Enterococci are intrinsically resistant to broad-spectrum antimicrobial agents and 
this limits the choice of drugs for treatment. The increased prevalence of enterococci 
pathogens in nosocomial infections worldwide has resulted in antimicrobials being used 
in greater frequency in hospitals (Kak and Chow, 2002). In animal husbandry, the same 
antimicrobial agents have been used widely as growth promoters (Kak and Chow, 2002). 
The acquisitions of antimicrobial resistance genes on plasmids or transposons from other 
organisms or spontaneous mutation have made enterococci increasingly resistant to 
various antimicrobial agents (Table 1.3) (Kak and Chow, 2002).    
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Table 1.3. Major patterns and mechanisms of resistance to antimicrobial agents in 
enterococci. 
 
High-level resistance to aminoglycosidesa. 
 Gentamicin 
 Kanamycin 
 Streptomycin 
 
Enzymatic (production of aminoglycoside-
modifying enzymes)b. 
 AAC(6’)-Ie + APH(2”)-Ia 
 AAC(6’)-Ii 
 APH(2”)-Iba; APH(2”)-Ic; 
APH(2”)-Id; APH(3’)-IIIa 
 ANT(3’)-Ia; ANT(4’)-Ia; ANT(4’)-
Ia; Alteration of the target (leading 
to decreased ribosomal binding) 
 
Resistance to glycopeptidesc. 
 Vancomycin      VanA 
 Teicoplanin        VanB 
                                VanC 
                                VanD 
                                VanE 
                                VanG 
 
Alteration of the target (modification of 
the peptidoglycan biosynthetic pathway) 
Resistance to β-lactams 
 Penicillin 
 Ampicillin 
Alteration of the target (altered penicillin-
binding proteins) 
Enzymatic (production of β-lactamase) 
 
Resistance to quinolones Alteration of the target (changes to the 
subunit A of DNA gyrase) 
 
Resistance to chloramphenicol Enzymatic (production of chloramphenicol 
acetyl transferase) 
 
Resistance to the MLS group 
 Macrolides (erythromycin) 
 Lincosamides (clindamycin) 
 Streptogramin B 
 
Enzymatic (production of methylating 
enzymes) 
Note: Adapted from reference (Facklam et al., 2002) (Appeared as table 6 and page 27 
in the source of original). 
a.Found in increasing frequencies in E. faecalis and E. faecium; b.AAC, 
acetyltransferases; APH, phosphotransferases; ANT, nucleotidyltransferases; c.VanA and 
VanB phenotypes are usually found in E. faecalis and E. faecium; VanC is usually 
associated with E. gallinarum (VanC1) and E. casseliflavus (VanC2/C3). VanD 
resistance has been described in E. faecium strains and VanE was found in E. faecalis.  
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1.2.4.1 Epidemiology and emergence of VRE and HLGR enterococci  
Since the initial recovery of VRE from patients in the United Kingdom and 
France, VRE have spread to other countries, including Australia, Canada, Denmark, 
Germany, Italy, Malaysia, The Netherlands, Spain, Sweden and the United States 
(Woodford et al., 1995, Cetinkaya et al., 2000). Molecular typing of enterococcal strains 
developed in the last two decades and serious problems arising from the emergence of 
VRE have intensified studies on epidemiology, colonization and infection of enterococci 
(Gilmore et al., 2002). Due to limited therapeutic options to treat VRE infections, it has 
become increasingly urgent to identify reservoirs for colonization and the routes of 
transmission of enterococci (Gilmore et al., 2002).  
Antimicrobial-susceptible enterococci and VRE seem to share the same 
environmental reservoirs (Gilmore et al., 2002). The hospital setting appears to play an 
important role in transmission of VRE, whereby medical equipment such as bed rails, 
tables, bed linen, urinals, blood pressure cuffs and stethoscopes can be easily 
contaminated (Bonilla et al., 1997, Bonten et al., 1998, Gilmore et al., 2002). One early 
VRE outbreak was caused by a contaminated electronic rectal thermometer that 
transmitted VRE from patient to patient (Livornese et al., 1992, Gilmore et al., 2002). 
Several studies have shown that environmental strains and strains isolated from patients 
are highly related (Bonten et al., 1996, Bonilla et al., 1997, Gilmore et al., 2002). 
Colonized patients with diarrhea may increase the risk of environment contamination 
with VRE as the density of VRE in their feces is increased due to the selective pressure 
of anti-anaerobic antimicrobials (Roghmann et al., 1997a, Donskey et al., 2000, Gilmore 
et al., 2002). VRE can persist for at least 2 months on laboratory bench, fabric and 
